Filing Flows › Organogenesis Holdings (ORGO) › Q1 2025
Organogenesis Holdings (ORGO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Organogenesis Holdings (ORGO) reported revenue of $86.7M for the first quarter 2025 (Q1 2025), -21% from a year earlier and -32% from the quarter before. Operating margin was -30.9%, net loss $18.8M (21.7% of revenue).
Organogenesis Holdings, Q1 2025: revenue $86.7M (-21% year over year), operating margin -30.9%, net loss $18.8M, operating cash flow −$19.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $86.7M | -32% | -21% |
| Operating profit | −$26.7M | — | — |
| Net earnings | −$18.8M | — | — |
| Operating cash flow | −$19.9M | — | — |
What changed
Revenue was $86.7M in Q1 2025, down 21% year over year and down 32% from the previous quarter. Advanced Wound Care was the largest line at 92% of revenue. Advanced Wound Care lost $23.9M year over year (down 23%), 103% of the total change.
Gross margin was 72.6%, down 1.3 points from a year earlier. Operating costs exceeded revenue by $26.7M, an operating margin of -30.9%. Operating expenses grew 5% against a revenue fall of 21%. The quarter ended with a net loss of $18.8M, after a profit of $7.7M the previous quarter.
Operating cash flow was −$19.9M. Non-cash charges added back $4.3M of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items used $8.7M. Capital expenditures of $3.6M exceeded it, leaving free cash flow of −$23.6M.
Questions
What was Organogenesis Holdings' revenue in the first quarter 2025?
Organogenesis Holdings (ORGO) reported revenue of $86.7M for the first quarter 2025 (Q1 2025), -21% from a year earlier and -32% from the quarter before.
Was Organogenesis Holdings profitable in the first quarter 2025?
Operating loss was $26.7M (-30.9% of revenue) and net loss $18.8M.